登录新浪财经APP 搜索【信披】查看更多考评等级 建信现金增利货币市场基金B类基金份额在中国建设银行销售渠道暂停大额申购、大额转换转入、定期 定额投资公告 公告送出日期：2025年9月27日 1. 公告基本信息 ■ 2.其他需要提示的事项 （1）建信现金增利货币市场基金B类基金份额将于2025年9月29日起在中国建设银行销售渠道暂停大额 申购、大额转换转入、定期定额投资业务，其他业务参照其他相应公告执行。 （3）投资者如有疑问，请拨打本基金管理人客户服务热线：400-81-95533 （免长途通话费），或登录 网站www.ccbfund.cn获取相关信息。 风险提示：本公司承诺以诚实信用、勤勉尽责的原则管理和运用基金财产，但不保证本基金一定盈利， 也不保证最低收益。基金的过往业绩不代表未来业绩。敬请广大投资者注意投资风险，理性投资。 特此公告。 建信基金管理有限责任公司 2025年9月27日 建信纳斯达克100指数型证券投资基金（QDII）基金暂停大额申购、定期定额投资公告 公告送出日期：2025年9月27日 1. 公告基本信息 ■ （2）建信现金增利货币市场基金B类基金份额在中国建设银行销售渠道暂停大额申购 ...

Group 1 - Company BaiLi TianHeng announced the completion of its new share issuance, with approximately 11.87 million shares issued at a price of 317 yuan per share, raising a total of about 3.764 billion yuan [1] - The newly issued shares are subject to a six-month transfer restriction from the date of issuance [1] - For the year 2024, BaiLi TianHeng's revenue composition is heavily weighted towards the pharmaceutical manufacturing sector, accounting for 99.97% of total revenue, with other businesses contributing only 0.03% [1] Group 2 - As of the latest report, BaiLi TianHeng's market capitalization stands at 149.5 billion yuan [2] - The insurance industry is experiencing significant growth, with a new type of insurance product seeing a 33-fold increase over five years, attracting interest from over 30 insurance companies [2]

证券代码：688506 证券简称：百利天恒 四川百利天恒药业股份有限公司 向特定对象发行 A 股股票 上市公告书 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 联席主承销商 深圳市前海深港合作区南山街道桂湾五 路128号前海深港基金小镇B7栋401 北京市西城区金融大街7号北京英蓝国 际金融中心十八层1807-1819室 二〇二五年九月 四川百利天恒药业股份有限公司 向特定对象发行 A 股股票上市公告书 特别提示 一、发行数量及价格 1、发行数量：11,873,817 股 2、发行价格：317.00 元/股 3、募集资金总额：人民币 3,763,999,989.00 元 4、募集资金净额：人民币 3,731,054,180.03 元 二、新增股票上市安排 本次发行新增股份将于限售期届满后的次一交易日起在上海证券交易所科 创板上市流通交易，如遇法定节假日或休息日，则顺延至其后的第一个交易日。 三、新增股份的限售安排 发行对象认购的本次发行的股票自发行结束之日起 6 个月内不得转让。本次 发行完成后至限售期满之日止，发行对象所取得公司本次向特定对象发行的股票 因公司分配股票股利、 ...

中信证券股份有限公司 关于四川百利天恒药业股份有限公司 2025 年度向特定对象发行 A 股股票 之 上市保荐书 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 二〇二五年九月 四川百利天恒药业股份有限公司 上市保荐书 声 明 中信证券股份有限公司接受四川百利天恒药业股份有限公司的委托，担任其 2025 年度向特定对象发行 A 股股票的保荐人。 中信证券及保荐代表人根据《中华人民共和国公司法》《中华人民共和国证 券法》《证券发行上市保荐业务管理办法》《上市公司证券发行注册管理办法》 《上海证券交易所科创板股票上市规则》《上海证券交易所上市公司证券发行与 承销业务实施细则》等有关法律、行政法规和中国证券监督管理委员会、上海证 券交易所的规定，诚实守信，勤勉尽责，严格按照依法制定的业务规则和行业自 律规范出具上市保荐书，并保证所出具文件真实、准确、完整。 本上市保荐书中如无特别说明，相关用语与《四川百利天恒药业股份有限公 司 2025 年度向特定对象发行 A 股股票募集说明书》中的含义相同。 1 | | | | 声 明 1 | | --- | | 目 录 2 | | 一、发行人基本 ...

证券代码：688506 证券简称：百利天恒 公告编号：2025-065 四川百利天恒药业股份有限公司 关于向特定对象发行股票发行结果暨股本变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 发行数量及价格 1、发行数量：11,873,817 股 2、发行价格：317.00 元/股 预计上市时间 四川百利天恒药业股份有限公司（以下简称"公司"、"发行人"）本次发行新 增股份 11,873,817 股已于 2025 年 9 月 25 日在中国证券登记结算有限责任公司上 海分公司办理完成登记、托管及限售手续。 本次发行新增股份为有限售条件流通股，将于限售期届满后的次一交易日起 在上海证券交易所科创板上市流通交易，如遇法定节假日或休息日，则顺延至其 后的第一个交易日。 发行对象所认购的本次发行股份自本次发行结束之日（即自本次向特定对象 发行的股票登记至名下之日）起六个月内不得转让。本次发行完成后，发行对象 基于本次发行所取得的上市公司向特定对象发行的股票，因上市公司分配股票股 利、资本公积转增股本等情形所衍生 ...

Core Viewpoint - The company has announced a private placement of 11.87 million shares at a price of 317 RMB per share, raising a total of 3.764 billion RMB, with a net amount of 3.731 billion RMB after deducting issuance costs [1] Summary by Relevant Sections - **Share Issuance Details** - The company issued 11.87 million shares at a price of 317 RMB per share [1] - The total funds raised amount to 3.764 billion RMB, with a net amount of 3.731 billion RMB after expenses [1] - **Registration and Trading** - The newly issued shares were registered and custodial procedures completed on September 25, 2025, at the Shanghai branch of China Securities Depository and Clearing Corporation Limited [1] - These shares are subject to a lock-up period and will be listed for trading on the Shanghai Stock Exchange's Sci-Tech Innovation Board after the lock-up period expires [1]

一瓶口服溶液挂网价558元，而同通用名普通片剂价格仅约8元，近70倍的价差背后，是亟待厘清的研发 成本，还是隐藏不当营销的灰色空间？ 云南省医疗保障局的一纸问询函，将上市公司百利天恒的全资子公司——四川百利药业推至聚光灯下。 9月24日，云南医保局就百利药业生产的马来酸依那普利口服溶液挂网价格高达558元发出公开问询，要 求其说明价格构成、销售利润、价差合理性及是否存在不当营销等四项问题。 这并不是该产品首次因价格问题引发关注。就在十天前的9月15日，上海阳光医药采购网已发布通知， 暂停包括该口服溶液在内的15个品规药品采购资格。接连被两地监管机构重点关注，折射出当前药品价 格监管的高压态势。 高价的质疑：剂型差异能否支撑70倍价差？ 马来酸依那普利是一种经典的血管紧张素转化酶抑制剂（ACEI），广泛用于治疗原发性高血压、肾性 高血压和充血性心力衰竭。该药的主流剂型为片剂，已多次被纳入国家集采，价格大幅下降。 以扬子江药业生产的马来酸依那普利片为例，经过集采两轮降价，从每盒19.15元降至5.66元，降幅达 70.4%。相比之下，百利药业生产的口服溶液剂型挂网价高达558元，与集采片剂形成近70倍的价差。 结 ...

Industry News - The China Nonferrous Metals Industry Association opposes "involution" competition in the copper smelting industry, emphasizing that it harms national and industry interests and deviates from high-quality development goals [1] - The Ministry of Commerce of China has added three US companies to the unreliable entity list and three others to the export control list, prohibiting them from engaging in import and export activities related to China [2] - The Ministry of Commerce calls for countries to jointly oppose unilateralism and protectionism, stressing that third-party interests should not be sacrificed due to coercion from others [2] - The total scale of public funds in China has surpassed 36 trillion yuan, marking the fifth historical high this year, with significant growth in stock and mixed funds [3] Company News - The stock of Upwind New Materials will be suspended for verification after rising over 1800% this year, marking its second suspension since a change in control was disclosed [4] - Ganfeng Lithium plans to introduce investors for a capital increase of up to 2.5 billion yuan for its subsidiary, Ganfeng Lithium Battery [4] - Jingfeng Mingyuan has entered mass production of its second-generation DrMos chips, which have been adopted by multiple clients, driving business growth [5] - Pingmei Shenma Group is undergoing a strategic restructuring, which will not significantly impact Pingmei Co.'s operations [5] - Lvtian Machinery clarifies that it has no relationship or business cooperation with Zhuhai Lvtian Machinery Co., Ltd. [6] - Xiamen International Trade holds a 0.67% stake in Mohr Thread through its investment fund [7] - Yuexiu Capital confirms that Mohr Thread is one of its investment projects, with no significant impact on current operating performance [8] - Dazhihui announces a share swap with Xiangcai Co., with a swap price of 9.53 yuan per share for Dazhihui [9] - Putailai has delivered dry and solid-state battery equipment to major domestic and international clients [10] - Hailunzhe's investment in Suzhou Yisheng Robotics is expected to positively impact future performance due to increased demand from Apple [11] - Hanyu Pharmaceutical plans to raise up to 968 million yuan for the development of semaglutide and other projects [12] - Tianen Kang's subsidiary has received approval for clinical trials of a new drug for rosacea, a first in the domestic market [12] - Baili Tianheng's innovative drug has been included in the list of breakthrough therapies by the National Medical Products Administration [13]

Group 1 - The Ministry of Commerce has added three US entities, including Huntington Ingalls Industries, to the export control list and three others to the unreliable entity list [1] - The digital RMB international operation center has officially launched in Shanghai, introducing three major business platforms: cross-border digital payment, blockchain service, and digital asset platform [1] - The Ministry of Education and the State Administration for Market Regulation have issued guidelines for the procurement and acceptance management of bulk food ingredients in school canteens, requiring suppliers to have legal operating qualifications [1] Group 2 - The Chinese government is initiating a trade and investment barrier investigation against Mexico due to proposed increases in import tariffs on products from non-free trade partners, including China [1] - The China Foreign Exchange Trading Center announced improvements to the "Swap Connect" mechanism, including an increase in the daily net limit to 45 billion yuan starting October 13, 2025 [1] - The China Securities Investment Fund Industry Association reported that the net asset value of public funds in China has surpassed 36 trillion yuan, reaching a historical high of 36.25 trillion yuan as of August 2025 [1] Group 3 - Five A-share companies, including Pingmei Shenma and Yicheng New Energy, announced that the Henan provincial government will implement a strategic restructuring of two major energy groups, which will not significantly impact their operations [1] - Hanyu Pharmaceutical announced plans to raise no more than 968 million yuan for the research and development of Semaglutide, including domestic injectable and US oral formulations [1] - The financing prosperity index for small and micro enterprises in August 2025 was reported at 54.22 points, indicating a slight decline from July, with overall credit structure continuing to optimize [1] Group 4 - Non-coal Holdings plans to implement a strategic restructuring involving its controlling shareholder [6] - China Railway recently won bids for 11 major projects with a total bid amount of 50.215 billion yuan [6] - Ganfeng Lithium's subsidiary is increasing capital and introducing investors for its lithium battery business [6]

Group 1 - The National Healthcare Security Administration (NHSA) has launched a "100-day action" to crack down on fraudulent medical insurance practices, aiming to eliminate illegal activities such as the resale of returned drugs by designated institutions [1] - This initiative reflects a zero-tolerance approach towards fraud and is expected to increase compliance pressure on medical institutions and pharmaceutical companies in the short term, ultimately helping to purify the industry ecosystem [1] Group 2 - Hanyu Pharmaceutical plans to raise up to 968 million yuan (approximately 136 million USD) through a private placement to fund projects including the development of Semaglutide, which is part of the GLP-1 drug class with significant market potential [2] - If the fundraising is successful, it will accelerate the company's GLP-1 drug development process and enhance its production capacity for peptide raw materials [2] Group 3 - XinNuoWei announced that its subsidiary received approval for clinical trials of Lecanemab, a monoclonal antibody drug for treating Alzheimer's disease, marking it as the first domestic biosimilar of this drug to gain clinical approval [3][4] - The approval of this biosimilar is expected to improve patient accessibility and alleviate financial burdens, as current treatments for Alzheimer's are predominantly high-priced products from multinational companies [4] Group 4 - Baillie Tianheng's ADC dual antibody drug, Iza-bren, has been included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) for treating advanced or metastatic urothelial carcinoma that has failed previous treatments [5] - This designation is likely to expedite the drug's market entry and could positively impact the company's stock price in the short term [5] Group 5 - Tainkang's subsidiary has received approval for clinical trials of CKBA cream for the treatment of rosacea, a first-class innovative drug in China for this condition [6][7] - The approval of this innovative drug could fill a gap in the domestic market for rosacea treatment, presenting considerable market potential if clinical trials demonstrate its efficacy [7]